BY AGENCY: We got the historic news a little over a year ago… the US Food and Drug Administration’s approval of an artificial pancreas for people with type 1 diabetes.
These folks must needle-poke their fingers several times a day to determine if their blood sugar is too high or too low, and then give themselves multiple daily shots of insulin to regulate their blood sugar levels.
This new technology combines an easier way to check blood sugars throughout the day (continuous glucose monitor) with software that automatically delivers the right amount of insulin at the right time through an insulin pump. Very cool. (read more)
BY LU RAHMAN: Rimidi will integrate its diabetes management software platform with Lilly’s integrated insulin management system in development.
The agreement between Rimidi and Lilly will strive to make diabetes management easier for approximately 30 million Americans with diabetes and their healthcare by helping people use insulin more effectively while optimising diabetes management within the normal clinical workflow.
“Diabetes management is a collaborative effort between people with diabetes and their healthcare providers. With the right support they can achieve better results together,” said Lucienne Ide, CEO of Rimidi. (read more)
BY MARIA COHUT: The main known causes for type 2 diabetes so far include obesity and lack of physical exercise — both of which can lead to insulin resistance — as well as a family history of the condition.
Insulin resistance occurs when muscles, liver, and fat cells become unable to use insulinappropriately, which ultimately leads to a dangerous rise in blood glucose levels.
Now, researchers from the Max Planck Institute of Psychiatry in Munich, Germany, have found that a protein called FKBP51 may also play a role in triggering type 2 diabetes. (read more)
BY VIRGINIA SCHAD: Automated systems that suspend basal insulin infusion when hypoglycemia is predicted may reduce hypoglycemia exposure without compromising glycemic control or quality of life in children and adolescents with type 1 diabetes, according to a 6-month, multicenter, controlled home trial published in Diabetes Care.
In an intent-to-treat analysis, researchers randomly assigned 154 patients with type 1 diabetes who were ages 8 to 20 years to either the control group (n=74) with sensor-augmented pump therapy (SAPT) alone or the intervention group (n=80) with SAPT and Suspend before low enabled (known as predictive low-glucose management [PLGM]). (read more)
BY NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES: Findings from the landmark NIDDK-funded study, Diabetes Control and Complications Trial (DCCT), and its follow-up, the Epidemiology of Diabetes Interventions and Complications (EDIC), continue to provide new insights that may change care for people with type 1 diabetes. Recent DCCT/EDIC research suggests that adjusting the frequency of eye screenings for people with type 1 diabetes based on their risk of severe eye problems, rather than on the automatic, annual schedule that is currently recommended, would result in fewer eye exams at lower cost. This adjustment could also result in quicker diagnosis and treatment of severe retinopathy, which can lead to vision loss.
Personal Risk Would Guide the Need for Eye Exams. For people with type 1 diabetes and a current average blood glucose level of 6 percent, the researchers recommend the following eye exam schedule for people with:
- no retinopathy, every 4 years
- mild retinopathy, every 3 years
- moderate retinopathy, every 6 months
- severe retinopathy, every 3 months (read more)